Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.93
0.145.02%
At close: -
$2.98
0.051.71%
After Hours: 5:47 PM EDT
Comments
Loading...
Taysha Gene Therapies Analyst Ratings and Price Targets | NASDAQ:TSHA | Benzinga
Taysha Gene Therapies Inc has a consensus price target of $5.93 based on the ratings of 16 analysts. The high is $10 issued by Wells Fargo on January 4, 2023. The low is $1 issued by Morgan Stanley on March 30, 2023. The 3 most-recent analyst ratings were released by Canaccord Genuity, JMP Securities, and Cantor Fitzgerald on May 16, 2025, April 28, 2025, and April 28, 2025, respectively. With an average price target of $7 between Canaccord Genuity, JMP Securities, and Cantor Fitzgerald, there's an implied 134.90% upside for Taysha Gene Therapies Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
JMP Securities
Cantor Fitzgerald
Needham
Chardan Capital
1calculated from analyst ratings
Analyst Ratings for Taysha Gene Therapies
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2025 | Buy Now | 202.01% | Canaccord Genuity | Whitney Ijem54% | $8 → $9 | Maintains | Buy | Get Alert |
| 04/28/2025 | Buy Now | 67.79% | JMP Securities | Silvan Tuerkcan46% | $5 → $5 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/28/2025 | Buy Now | 134.9% | Cantor Fitzgerald | Kristen Kluska68% | $7 → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 04/10/2025 | Buy Now | 101.34% | Needham | Gil Blum49% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 101.34% | Needham | Gil Blum49% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2025 | Buy Now | 134.9% | Chardan Capital | Geulah Livshits46% | $7 → $7 | Maintains | Buy | Get Alert |
| 01/06/2025 | Buy Now | 101.34% | Needham | Gil Blum49% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2024 | Buy Now | 168.46% | Canaccord Genuity | Whitney Ijem54% | $6 → $8 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | 134.9% | Chardan Capital | Geulah Livshits46% | $7 → $7 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | 101.34% | Needham | Gil Blum49% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 134.9% | Cantor Fitzgerald | Kristen Kluska68% | $7 → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 11/12/2024 | Buy Now | 67.79% | JMP Securities | Silvan Tuerkcan46% | $5 → $5 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/12/2024 | Buy Now | 134.9% | Cantor Fitzgerald | Kristen Kluska68% | $7 → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 11/12/2024 | Buy Now | 101.34% | Needham | Gil Blum49% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2024 | Buy Now | 101.34% | Canaccord Genuity | Whitney Ijem54% | $7 → $6 | Maintains | Buy | Get Alert |
| 08/13/2024 | Buy Now | 134.9% | Chardan Capital | Geulah Livshits46% | $7 → $7 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | 101.34% | Needham | Gil Blum49% | $7 → $6 | Maintains | Buy | Get Alert |
| 07/26/2024 | Buy Now | 134.9% | Needham | Gil Blum49% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 07/23/2024 | Buy Now | 134.9% | Needham | Gil Blum49% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 07/01/2024 | Buy Now | 134.9% | Piper Sandler | Christopher Raymond54% | $9 → $7 | Maintains | Overweight | Get Alert |
| 06/27/2024 | Buy Now | 67.79% | BMO Capital | Keith Tapper51% | → $5 | Initiates | → Outperform | Get Alert |
| 06/20/2024 | Buy Now | 67.79% | JMP Securities | Silvan Tuerkcan46% | $5 → $5 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/20/2024 | Buy Now | 134.9% | Cantor Fitzgerald | Kristen Kluska68% | $7 → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 06/19/2024 | Buy Now | 134.9% | Needham | Gil Blum49% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 06/18/2024 | Buy Now | 134.9% | Chardan Capital | Geulah Livshits46% | $7 → $7 | Maintains | Buy | Get Alert |
| 06/17/2024 | Buy Now | 134.9% | Needham | Gil Blum49% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 05/28/2024 | Buy Now | 134.9% | Cantor Fitzgerald | Kristen Kluska68% | $7 → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 05/15/2024 | Buy Now | 134.9% | Cantor Fitzgerald | Kristen Kluska68% | $7 → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 05/15/2024 | Buy Now | 134.9% | Needham | Gil Blum49% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 168.46% | Jefferies | Eun Yang33% | $2 → $8 | Assumes | Hold → Buy | Get Alert |
| 05/02/2024 | Buy Now | 134.9% | Needham | Gil Blum49% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 04/30/2024 | Buy Now | 134.9% | Cantor Fitzgerald | Kristen Kluska68% | $7 → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 04/19/2024 | Buy Now | 134.9% | Cantor Fitzgerald | Kristen Kluska68% | $7 → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 04/18/2024 | Buy Now | 134.9% | Cantor Fitzgerald | Kristen Kluska68% | $7 → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 04/11/2024 | Buy Now | 134.9% | Needham | Gil Blum49% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 202.01% | Piper Sandler | Christopher Raymond54% | → $9 | Initiates | → Overweight | Get Alert |
| 03/21/2024 | Buy Now | 134.9% | Canaccord Genuity | Whitney Ijem54% | → $7 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2024 | Buy Now | 134.9% | Chardan Capital | Geulah Livshits46% | $5 → $7 | Maintains | Buy | Get Alert |
| 03/20/2024 | Buy Now | 67.79% | JMP Securities | Silvan Tuerkcan46% | $5 → $5 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/20/2024 | Buy Now | 134.9% | Cantor Fitzgerald | Kristen Kluska68% | → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | Buy Now | 134.9% | Needham | Gil Blum49% | $5 → $7 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 67.79% | Needham | Gil Blum49% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2023 | Buy Now | 134.9% | Cantor Fitzgerald | Kristen Kluska68% | $7 → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 11/15/2023 | Buy Now | 134.9% | Cantor Fitzgerald | Kristen Kluska68% | $6 → $7 | Maintains | Overweight | Get Alert |
| 09/20/2023 | Buy Now | 67.79% | Needham | Gil Blum49% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2023 | Buy Now | 67.79% | Truist Securities | Joon Lee76% | $6 → $5 | Maintains | Buy | Get Alert |
| 09/20/2023 | Buy Now | 101.34% | Canaccord Genuity | Whitney Ijem54% | $7 → $6 | Maintains | Buy | Get Alert |
| 08/16/2023 | Buy Now | 134.9% | Canaccord Genuity | Whitney Ijem54% | $13 → $7 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 101.34% | Truist Securities | Joon Lee76% | $2 → $6 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 34.23% | JMP Securities | Silvan Tuerkcan46% | → $4 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/15/2023 | Buy Now | 168.46% | Baird | Jack Allen 35% | $6 → $8 | Maintains | Outperform | Get Alert |
| 08/15/2023 | Buy Now | 67.79% | Chardan Capital | Geulah Livshits46% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | Buy Now | 67.79% | Needham | Gil Blum49% | $6 → $5 | Maintains | Buy | Get Alert |
| 08/14/2023 | Buy Now | 134.9% | Cantor Fitzgerald | Kristen Kluska68% | $2 → $7 | Maintains | Overweight | Get Alert |
| 07/06/2023 | Buy Now | 336.24% | Canaccord Genuity | Whitney Ijem54% | → $13 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | Buy Now | 67.79% | Chardan Capital | Geulah Livshits46% | → $5 | Reiterates | → Buy | Get Alert |
| 06/29/2023 | Buy Now | 101.34% | Needham | Gil Blum49% | → $6 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | -32.89% | Truist Securities | Joon Lee76% | $3 → $2 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | 101.34% | Needham | Gil Blum49% | → $6 | Reiterates | Buy → Buy | Get Alert |
| 03/30/2023 | Buy Now | 34.23% | JMP Securities | Silvan Tuerkcan46% | → $4 | Reiterates | → Market Outperform | Get Alert |
| 03/30/2023 | Buy Now | -66.44% | Morgan Stanley | Michael Lapides60% | $3 → $1 | Maintains | Equal-Weight | Get Alert |
| 03/30/2023 | Buy Now | -32.89% | Cantor Fitzgerald | Kristen Kluska68% | $13 → $2 | Maintains | Overweight | Get Alert |
| 03/30/2023 | Buy Now | 67.79% | Chardan Capital | Geulah Livshits46% | $6 → $5 | Maintains | Buy | Get Alert |
| 03/29/2023 | Buy Now | 0.67% | Truist Securities | Joon Lee76% | $4 → $3 | Maintains | Buy | Get Alert |
| 03/29/2023 | Buy Now | 101.34% | Needham | Gil Blum49% | → $6 | Reiterates | → Buy | Get Alert |
| 02/02/2023 | Buy Now | — | BTIG | Yun Zhong35% | — | Downgrade | Buy → Neutral | Get Alert |
| 02/01/2023 | Buy Now | 336.24% | Canaccord Genuity | Whitney Ijem54% | $17 → $13 | Maintains | Buy | Get Alert |
| 02/01/2023 | Buy Now | 101.34% | Chardan Capital | Geulah Livshits46% | $16 → $6 | Maintains | Buy | Get Alert |
| 02/01/2023 | Buy Now | 34.23% | Truist Securities | Joon Lee76% | $15 → $4 | Maintains | Buy | Get Alert |
| 02/01/2023 | Buy Now | 336.24% | Cantor Fitzgerald | Kristen Kluska68% | $24 → $13 | Reiterates | → Overweight | Get Alert |
| 02/01/2023 | Buy Now | -49.66% | Jefferies | Eun Yang33% | $14 → $1.5 | Downgrade | Buy → Hold | Get Alert |
| 02/01/2023 | Buy Now | 34.23% | JMP Securities | Silvan Tuerkcan46% | $6 → $4 | Maintains | Market Outperform | Get Alert |
| 02/01/2023 | Buy Now | 101.34% | Baird | Jack Allen 35% | $10 → $6 | Maintains | Outperform | Get Alert |
| 02/01/2023 | Buy Now | 101.34% | Needham | Gil Blum49% | $16 → $6 | Maintains | Buy | Get Alert |
| 01/27/2023 | Buy Now | 0.67% | Morgan Stanley | Michael Ulz62% | → $3 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 01/19/2023 | Buy Now | 101.34% | JMP Securities | Silvan Tuerkcan46% | $20 → $6 | Maintains | Market Outperform | Get Alert |
| 01/04/2023 | Buy Now | 235.57% | Wells Fargo | Yanan Zhu39% | $14 → $10 | Maintains | Overweight | Get Alert |
| 11/10/2022 | Buy Now | 571.14% | JMP Securities | Silvan Tuerkcan46% | $22 → $20 | Maintains | Market Outperform | Get Alert |
| 11/09/2022 | Buy Now | 436.91% | Chardan Capital | Geulah Livshits46% | $32 → $16 | Maintains | Buy | Get Alert |
| 11/09/2022 | Buy Now | 0.67% | Goldman Sachs | Salveen Richter52% | $16 → $3 | Downgrade | Buy → Neutral | Get Alert |
| 11/09/2022 | Buy Now | 436.91% | Needham | Gil Blum49% | $18 → $16 | Maintains | Buy | Get Alert |
| 11/08/2022 | Buy Now | 436.91% | Canaccord Genuity | Whitney Ijem54% | → $16 | Initiates | → Buy | Get Alert |
| 10/26/2022 | Buy Now | 604.7% | Baird | Jack Allen 35% | $26 → $21 | Maintains | Outperform | Get Alert |
| 10/25/2022 | Buy Now | 504.03% | Needham | Gil Blum49% | $20 → $18 | Maintains | Buy | Get Alert |
| 08/12/2022 | Buy Now | 67.79% | Wedbush | Laura Chico46% | $9 → $5 | Maintains | Outperform | Get Alert |
| 08/12/2022 | Buy Now | 973.83% | Chardan Capital | Geulah Livshits46% | $34 → $32 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | 436.91% | Goldman Sachs | Salveen Richter52% | $27 → $16 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Taysha Gene Therapies (TSHA) stock?
The latest price target for Taysha Gene Therapies (NASDAQ:TSHA) was reported by Canaccord Genuity on May 16, 2025. The analyst firm set a price target for $9.00 expecting TSHA to rise to within 12 months (a possible 202.01% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Taysha Gene Therapies (TSHA)?
The latest analyst rating for Taysha Gene Therapies (NASDAQ:TSHA) was provided by Canaccord Genuity, and Taysha Gene Therapies maintained their buy rating.
When was the last upgrade for Taysha Gene Therapies (TSHA)?
There is no last upgrade for Taysha Gene Therapies
When was the last downgrade for Taysha Gene Therapies (TSHA)?
The last downgrade for Taysha Gene Therapies Inc happened on February 2, 2023 when BTIG changed their price target from N/A to N/A for Taysha Gene Therapies Inc.
When is the next analyst rating going to be posted or updated for Taysha Gene Therapies (TSHA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Taysha Gene Therapies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Taysha Gene Therapies was filed on May 16, 2025 so you should expect the next rating to be made available sometime around May 16, 2026.
Is the Analyst Rating Taysha Gene Therapies (TSHA) correct?
While ratings are subjective and will change, the latest Taysha Gene Therapies (TSHA) rating was a maintained with a price target of $8.00 to $9.00. The current price Taysha Gene Therapies (TSHA) is trading at is $2.98, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
